Article info
PDFOriginal research
Institutional conflict of interest: attempting to crack the deferiprone mystery
- Correspondence to Professor Arthur Schafer, University of Manitoba, Winnipeg, R3T 2N2, Canada; Arthur.schafer{at}umanitoba.ca
Citation
Institutional conflict of interest: attempting to crack the deferiprone mystery
Publication history
- Received April 9, 2019
- Revised December 12, 2019
- Accepted December 22, 2019
- First published January 8, 2020.
Online issue publication
January 09, 2022
Article Versions
- Previous version (9 January 2022).
- Previous version (9 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Whistleblower’s decades long fight to save patients from dangerous research
- The Olivieri debacle: where were the heroes of bioethics?
- Biomedical conflicts of interest: a defence of the sequestration thesis—learning from the cases of Nancy Olivieri and David Healy
- Introduction to The Olivieri symposium
- Thalassaemia major: the murky story of deferiprone
- Better governance in academic health sciences centres: moving beyond the Olivieri/Apotex Affair in Toronto
- Post-trial period surveillance for randomised controlled cardiovascular studies: submitted protocols, consent forms and the role of the ethics board
- Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial
- Science, politics, ethics and the pandemic
- Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial